Co-Authors
This is a "connection" page, showing publications co-authored by James Battiste and Kar-Ming Fung.
Connection Strength
0.549
-
OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth. Transl Oncol. 2019 Feb; 12(2):320-335.
Score: 0.163
-
A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007. J Cell Mol Med. 2022 01; 26(2):570-582.
Score: 0.050
-
H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. J Neurooncol. 2021 Dec; 155(3):225-234.
Score: 0.050
-
ELTD1 as a multi-focal target for malignant gliomas: preclinical studies. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab132.
Score: 0.049
-
Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model. Transl Oncol. 2020 Mar; 13(3):100737.
Score: 0.045
-
Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model. J Cell Mol Med. 2020 01; 24(2):1738-1749.
Score: 0.044
-
Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment. Am J Nucl Med Mol Imaging. 2019; 9(1):93-109.
Score: 0.041
-
Co-occurrence of astrocytoma and astroblastoma: Case report and literature review. Neuropathology. 2018 Oct; 38(5):516-520.
Score: 0.040
-
ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models. Neuro Oncol. 2017 02 01; 19(2):175-185.
Score: 0.036
-
Tumor necrosis-initiated complement activation stimulates proliferation of medulloblastoma cells. Inflamm Res. 2015 Apr; 64(3-4):185-92.
Score: 0.031